Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Mohit Yadav reaffirmed government's commitment to improve competitiveness, enhance export capabilities and support the country's transition from volume-driven to value-driven exports
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
